To date, no drugs targeting DYNLT1 have been developed, while VBIT-12, a specific small molecule inhibitor targeting VDAC1, exists to improve amyotrophic lateral sclerosis (ALS) in mice (Shteinfer-Kuzmine et al. 2022), alleviate acute liver injury in mice (Niu et al. 2022), and alleviate inflammatory bowel disease due to mitochondrial dysfunction in mice (Verma et al. 2022), and the application of VBIT-12 in cancer has not reported. Here, VDAC1 is linked to inflammatory bowel disease.